Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ONWD.BR
Strong SellOnward Medical N.V. · Healthcare · Netherlands · $199M · Avg Vol: $237K/d
COMPANY DESCRIPTION
Onward Medical N.V. is a clinical-stage medical technology company developing innovative neuromodulation therapies to restore movement, independence, and health in people with spinal cord injuries. The company competitive moat is established by its proprietary ARC Therapy platform, which delivers targeted electrical stimulation to the spinal cord and has received multiple FDA Breakthrough Device designations. It operates as a highly specialized biotechnology pioneer at the intersection of neurostimulation and rehabilitative medicine.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0.1M | 68.0K | 0.2M | 3.8M | 231.2% | 5.5M | 12.2M | 30.6M | 184.4% |
| EPS (EUR) | -3.62 | -0.47 | -0.52 | -0.80 | -0.75 | — | -0.91 | -0.84 | -0.64 | — |
| Shares | — | 69.5M | 69.5M | 44.6M | 56.0M | -19.4% | 69.5M | — | — | — |
| Debt | — | 14.4M | 16.9M | 15.1M | 13.7M | -1.7% | 13.8M | — | — | — |
| Equity | — | 52.6M | 17.9M | 48.1M | 55.3M | 1.7% | — | — | — | — |
| Op CF | — | -26.7M | -32.3M | -31.8M | -39.1M | — | -39.3M | — | — | — |
| Inv CF | — | -20.4M | 19.6M | -0.1M | -0.4M | — | — | — | — | — |
| Fin CF | — | -0.6M | 0.8M | 62.6M | 47.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ONWD.BR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ONWD.BR | Onward Medical N.V.(you) | $199M | 4 | Strong Sell |
| PRQR | ProQR Therapeutics N.V. | $323M | 30 | Sell |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.0B | 9 | Strong Sell |
| PHARM.AS | Pharming Group N.V. | $815M | 36 | Hold |
| QURE | uniQure N.V. | $3.4B | 18 | Strong Sell |
| ARGX | argenx SE | $63.6B | 75 | Buy |
| RDC.DE | Redcare Pharmacy NV | $1.5B | 54 | Hold |
| QGEN | Qiagen N.V. | $8.9B | 65 | Buy |
| PHG | Koninklijke Philips N.V. | $26.1B | 84 | Strong Buy |
Peer medians: ROE 10.2% · P/E 22.2x · Gross margin 66.4%